STEMart announces the expansion of its genetic toxicology capabilities with the In Vivo Rat Micronucleus Test services.

Nicholas Richardson, DO, at Precision for Medicine, breaks down minimal residual disease and MRD negativity as FDA end points for faster myeloma approvals. Under this framework, MRD negativity is ...

The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing. WILMINGTON, ...

A recent review concluded that artificial intelligence (AI) is rapidly transforming the diagnosis and treatment of haematological malignancies by enhancing diagnostic accuracy and ...

An fresh look at trial results that propelled the only FDA approval of a chimeric antigen receptor (CAR) T-cell therapy for mantle cell lymphoma (MCL) shows prior treatment with ibrutinib, a ...

The successful clinical validation of AlloHeme represents a key milestone in CareDx's Transplant+ strategy, expanding the Company's precision medicine capabilities into cell therapy, hematology, and ...

As rural hospitals across the United States continue to face persistent workforce shortages, international direct hire nurses are playing a growing role in maintaining access to care and strengthening ...

A new study may change the way scientists think about the distance traveled by tiny bubbles carrying signals between cells ...

Waters (NYSE:WAT) executives said the company closed out 2025 with a “strong finish” and entered 2026 with a major portfolio ...

BDX completes its Biosciences & Diagnostic spin-off and Waters merger, securing $4B in proceeds as it pivots to a pure-play ...

SustainCERT’s validation gives companies confidence that Regrow can underpin high‑integrity climate claims”— Lucia von ...